Journal article

Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis

Nava Ferdowsi, Molla Huq, Wendy Stevens, Marie Hudson, Mianbo Wang, Tien Tay, Jodie L Burchell, Sam Mancuso, Candice Rabusa, Vijaya Sundararajan, David Prior, Susanna M Proudman, Murray Baron, Mandana Nikpour, Tracy Frech, Marie Hudson, Susanna Proudman, Wendy Stevens, Tien Tay, Souyma Chatterjee Show all

Annals of the Rheumatic Diseases | BMJ PUBLISHING GROUP | Published : 2019


Awarded by NHMRC Fellowship

Awarded by Canadian Institutes of Health Research (CIHR)

Funding Acknowledgements

The development of the SCTC-DI was supported by SCTC Working Group grants. The Australian Scleroderma Cohort Study is supported by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer. A/Prof Nikpour holds an NHMRC Fellowship (APP1126370). The Canadian Scleroderma Research Group (CSRG) is funded by the Canadian Institutes of Health Research (CIHR) (grant #FRN 83518), the Scleroderma Society of Canada and its provincial Chapters, Scleroderma Society of Ontario, Scleroderma Society of Saskatchewan, Sclerodermie Quebec, Cure Scleroderma Foundation, INOVA Diagnostics (San Diego, CA), Fooke Laboratorien (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen (Neuried, Germany), Fonds de la rechercheen sante du Quebec (FRSQ), the Canadian Arthritis Network (CAN) and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, QC. The CSRG has also received educational grants from Pfizer and Actelion pharmaceuticals.